Amgen: Bone Diseases, Metabolic trials

The registry lists 19 Bone Diseases, Metabolic studies with Amgen as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 7Phase 2 4Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)CompletedNCT01825785Phase 1Results posted
• Effects of Denosumab on the Pharmacokinetics of EtanerceptTerminatedNCT01294397Phase 1Results posted
• A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese WomenCompletedNCT01101061Phase 1Results posted
• A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal WomenCompletedNCT01059435Phase 1Results posted
• Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With OsteoporosisCompletedNCT00980174Phase 3Results posted
• A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone MassCompletedNCT00950950Phase 1Results posted
• Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone LossCompletedNCT00925600Phase 3Results posted
• Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00896532Phase 2Results posted
• A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With DenosumabCompletedNCT00890981Phase 3Results posted
• A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With DenosumabCompletedNCT00887965Phase 2Results posted
• Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of OsteoporosisCompletedNCT00523341Phase 3Results posted
• A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral DensityCompletedNCT00515463Phase 3Results posted
• A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.CompletedNCT00330460Phase 3Results posted
• An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00325468Phase 3Results posted
• A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00293813Phase 2Results posted
• AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerCompletedNCT00089661Phase 3Results posted
• Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00043186Phase 2Results posted
• An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral DensityCompletedNCT01101048Phase 1
• A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal WomenCompletedNCT00902356Phase 1